VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)

Stock Information for Vistagen Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.